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An eﬀective means to eradicate latent reservoirs in HIV-1-infected individuals remains elusive. Attempts to purge these reservoirs
were undertaken over a decade ago without success. The subsequent lapse in further clinical attempts since may have been justiﬁed
as ourknowledge of themechanisms which underpin thelatent state stillevolves. Althoughadditional novelmolecular antagonists
of HIV-1 latency have subsequently been reported, these candidate agents have not been tested in human trials for reservoir
ablation. This review provides an overview of the protein kinase C (PKC) pathway which can be modulated by small molecular




Administration of highly active anti-retroviral therapy
(HAART) to HIV-1-infected individuals results in eﬀective
suppression of viral replication in metabolically active cells
bearing integrated viral DNA. However, a small population
of infected cells is refractive to HAART treatment as a con-
sequence of being quiescent and/or not actively expressing
virus products [1–5]. This small population of cells, com-
prised largely of infected CD4+ resting T cells, constitutes
the HAART-persistent latent reservoir. Most cells in this
silent reservoir have long half lives [6, 7] and are hidden
from immune surveillance which permits them to remain
as a stable source for de novo v i r a lp r o d u c t i o nu p o nr e a c -
tivation. One strategy for eradication of this reservoir rests
upon the premise that cellular activation with concomitant
upregulation of viral expression will hasten its elimination
[8–11]. Cellular activation typically shortens the half-life of
a cell relative to its quiescent counterpart, and a cell, actively
expressing viral antigens, would be a more favorable target
for immune clearance [12].
Some time ago, several clinical trials were attempted
to eradicate or diminish the presence of latent reservoirs
usingthecellularactivators,OKT3andIL-2,whichprimarily
target T-cell responses [13–18] .T h e s et r i a l sw e r ei n e ﬀectual
although genotypic alterations of reservoir virus in treated
individuals were noted [19]. Nonetheless, these attempts
clearly indicated that a broader armamentarium of agents or
multiple clinical interventions were required to accomplish
the elusive goal of complete reservoir eradication. The list
of candidates in this armamentarium has grown to be
quite lengthy. They include small hydrophobic agents within
the phorbol ester family of compounds [20], as well as
bryostatin-1, a macrolide lactone [21]. The phorbol ester
family of compounds and select lactones modulate the
protein kinase C (PKC) pathway which induces latent HIV-
1 expression [20, 21]. Chromatin remodeling agents [22–
26] and select cytokines, primarily the interleukins or inter-
ferons, have also been shown to upregulate viral expression
from latent proviruses. [27–30].
Clearly, compounds which upregulate latent HIV-1
expression may have clinical utility toward the eradication2 Advances in Virology
of HIV-1 HAART-persistent reservoirs. Their elimination
would eﬀectively represent a cure for HIV-1 infection. This
paper will focus upon PKC as one pathway that may be
modulated by small molecular agents toward this goal.
2. Overview of the ProteinKinase C Pathway
The protein kinase C (PKC) signal cascade is comprised of,
and regulated by, several isoforms [31, 32]. Each isoform
exhibits select characteristics as well as varying patterns of
expression in speciﬁc cell types. The PKC cascade can aﬀect
receptor upregulation or downregulation, membrane and
cytoskeleton remodeling, and positive or negative regulation
of transcription to mediate speciﬁc processes within the
cell. These activities can have global eﬀects on cellular
functions, in particular, growth, attachment, diﬀerentiation,
maturation, and death [31, 32]. These varied functions are
typically mediated by PKC phosphorylation of serine and
threonine residues of downstream signaling factors [33, 34].
These phosphorylated factors then serve as intermediaries in
the transduction of signals to various cellular locations in
order to accomplish speciﬁc eﬀector functions.
3. Stimulationof the PKC Pathway
PKC pathway activation involves the participation of the
phospholipase C (PLC) superfamily of proteins for most
natural cellular processes. PLCs participate in phosphat-
idylinositol-4,5-bisphosphate (PIP2) metabolism and lipid
signaling pathways in a calcium-dependent manner. Similar
to the PKC pathway, the PLC superfamily consists of
many isoforms which diﬀer in their mode of activation,
expression levels, catalytic regulation, cellular localization,
and membrane binding aﬃnity [33]. All are capable of
catalyzing the hydrolysis of PIP2 into two important second
messenger molecules: diacylglycerol (DAG) and inositol-
1,4,5-trisphosphate(IP3).Thesetwosecondmessengershave
diﬀerential cellular eﬀects. IP3 molecules diﬀuse through
the cytoplasm and bind to the endoplasmic reticulum (ER)
resulting in the opening of calcium channels [31–34]. The
released calcium from the ER into the cytoplasm is free
to bind important regulatory proteins including but not
restricted to calmodulin and calcineurin. The binding of
calcium to calmodulin mediates critical organismal pro-
cesses such as inﬂammation, metabolism, apoptosis, smooth
muscle contraction, intracellular movement, short-term and
long-term memory, nerve growth, and the immune response
[35–37].
DAG, the other by-product of PLC cleavage, can activate
PKC in cooperation with calcium [31–33]. The kinase
activity of phosphorylated PKC then phosphorylates various
protein targets and these targets in turn transduce signals
broadly through select signaling pathways. These initial
eventsareillustratedinFigure 1.Importantly ,naturalorsyn-
thetic phorbol esters, like phorbol-12-myristate 13-acetate
(PMA), a tumor promoting agent, or prostratin, a non-
tumor promoting phorbol, as well as select lactones like
bryostatin-1 can serve as mimetics or analogues of DAG to
modulate PKC pathway activity for the induction of latent
proviral expression [20–22].
4. PKC Isoform Speciﬁcity and Action
All PKC isoforms consist of a regulatory domain tethered to
a catalytic domain [31, 32]. There are two primary classes
of PKC protein isoforms. Calcium-dependent classical PKC
isoforms (cPKCs), require calcium for their activity, while
calcium-independent isoforms (nPKCs) do not. The cPKCs
(α, βI, βII, and γ) are calcium and DAG-dependent, whereas
t h en o v e lP K C s( δ, ε, η,a n dθ) are calcium-independent
but DAG-responsive. A third class of PCKs is referred to as
atypical includes the isoforms ξ and λ/l that uniquely lack
responses to calcium and DAG [31, 32, 38].
A highly conserved cysteine-rich motif in the regulatory
region of most PKC isoforms acts as the speciﬁc docking
receptor for DAG as well as for phorbol esters like PMA [31].
This conserved DAG/PMA-binding domain, referred to as
C1, binds two zinc ions in a zinc ﬁnger-like structure which
is comprised of six cysteines and two histidines [38, 39]. The
C1 domain displays a hydrophobic surface surrounding a
hydrophilic cleft. Studies suggest that DAG, phorbol esters
or DAG lactone binding to C1 conceals the hydrophilic
cleft reducing the overt charge of this domain [38–41]. This
facilitates hydrophobic interaction of PKC complexes with
the cytoplasmic portion of the plasma membrane or other
membranous cellular surfaces [38–41]. This translocation
of PKCs in complexes with DAG or DAG analogues to the
plasma membrane and other sub-cellular localizations initi-
ates the PKC activation cascade. It is of interest that various
phorbol derivatives, with diﬀering aﬃnities for the C1
domain of PKC isoforms, elicit diﬀerent cellular responses
as well as the degree to which these responses are sustained




The non-tumor-promoting deoxyphorbol esters which acti-
vate PKC emerged as candidates for HIV-1 latent reservoir
eradication from studies initially performed at the National
Cancer Institute (NCI). NCI investigated antiviral properties
of several ethnobotanical compounds including the novel
phorbol ester, prostratin. Prostratin had ﬁrst been identiﬁed
as a constituent of the poisonous New Zealand plant Pimelea
prostrata [42]. As observed by the ethnobotanist, Paul Cox,
prostratin was later detected in bark extracts from the plant,
Homalanthus nutans, used by native island tribesmen in
Samoa as a remedy for jaundice [43]. On this basis it was
speculated to have antiviral properties. Initial investigations
of the puriﬁed compound by NCI revealed that prostratin
inhibited infectious viral spread but readily upregulated
latent HIV-1 from the quiescently infected cell lines, ACH2
and U1 [44, 45]. Prior to the introduction of HAART, there




















Figure 1: Overview of the mechanistic steps involved in PKC modulation toward the upregulation of latent HIV-1. PKC modulating agents
represent functional analogues of DAG that similarly activate the PKC cascade.
produce additional virus from within the cells of HIV-1-
infected patients.
The view for prostratin’s utility evolved with the sub-
sequent advent of HAART. HAART potently prevents viral
spread, presumably including any virus that could subse-
quently be expressed from latent proviral DNA. Conse-
quently, prostratin was proposed as a candidate for adju-
vant therapy in conjunction with HAART to eradicate the
latent reservoir via cellular activation without the danger
of viral spread or latent reservoir reseeding [46]. Impor-
tantly, early studies clearly indicated that prostratin and
other non-tumor-promoting phorbol esters, including 12-
deoxyphorbol-13-phenylacetate (DPP), readily reactivated
latent virus from primary HIV-1-infected patient resting T
cells [20, 46–48]. This same ability has been demonstrated
more recently with lactone analogues of DAG that also serve
as PKC-modulating agents [21, 40].
Of interest is the diﬀerential targeting of PKC isoforms
by phorbol esters versus certain synthetic or natural DAG
analogue lactones. For example, the induction of latent HIV-
1 is mediated by the sequential action of PKC α and PKC
θ isoforms in PMA or prostratin-treated T cells [49] while
bryostatin-1 treatment accomplishes reactivation through
PKC α and PKC δ [21].
The outcome of PKC isoform activation or modu-
lation by phorbol esters and structurally related agents
occurs downstream via transduction through at least the
ERK1/ERK2 mitogen-activated protein kinase pathway [50].
As shown in Figure 1, this pathway stimulates IKK-depend-
ent phosphorylation and degradation of IκBα, leading to
activation of NF-κB[ 50, 51]. As shown in Figure 2,f r e eN F -
κB is then competent for translocation and binding to sites
in the enhancer region of the HIV-1 long terminal repeat
(LTR). The binding of NF-κB to the LTR is required for high-
level transcription of HIV-1 RNA and upregulation in the
expression of latent reservoir virus. NF-κB upregulation of
latent proviral DNA in reservoir cells is synergized by the
stimulation of the activator protein-1 (AP-1). AP-1 activity
is stimulated through JNK and mitogen-activated protein
kinase signaling pathways which is triggered upstream by
PKC action [50, 51]. As shown in Figure 2, the transcription
factors AP-1, as well as SP-1, which recognizes GC-rich4 Advances in Virology
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Figure 3: Morphological and apoptotic eﬀects of PMA and prostratin on select cell lines. Top panel: 293 adherent cells. Lower panel: Jurkat
cells. Concentrations of prostratin at or below 10μM, higher than required to upregulate latent HIV-1, do not markedly alter morphogenesis
or induce apoptosis. Concentrations >10μMa ﬀect both cellular processes.
sequences, have their binding sites located in the HIV-1
LTR enhancer region. It is likely that NF-κB, AP-1, and Sp-
1 are cooperative toward accomplishing robust expression
of latent viral reservoirs; however, Nf-κB appears to be the
central mediator for latent provirus expression [51–53]. An
ancillary activity of PKC activation is the phosphorylation
of Tat, a virally encoded accessory protein required for
transcript elongation to produce full-length HIV-1 RNAs
[54].
6. Concerns of Modulating PKC Activity
There have been ongoing concerns regarding the clinical
use of PKC modulators for HIV-1 reservoir eradication,
particularly the phorbol ester family of compounds. As
previously stated, phorbol esters activate PKC in multiple
cell types raising the issue that systemic eﬀects in treated
patients would be broader than necessary given the limited
cell types in the latent reservoir necessary to be targeted for
eradication.
In vitro studies have shown that PMA advances the
expression of monocyte and macrophage surface markers
in promonocytic and myelocytic leukemia cell lines as
well as primary leukemic cells [55]. Indications of cellular
diﬀerentiation in response to PMA and other phorbol esters
include morphological alterations, reduction in the rate of
replication,andremodelingofcellularﬁbernetworksleading
to either increased cellular adherence to plastic or decreased
cell-cell contact [46, 55]. Further, alterations in receptor
expression aﬀect responses to external or internal cell
signaling.
Alterationsincell-cellcontactandtheinductionofapop-
tosis by phorbol ester exposure can be easily demonstrated
and are evident in Figure 3. The cell lines, representing
immortalized embryonic kidney 293-A and transformed
Jurkat T lymphocytes, were treated with concentrations of
prostratinandPMAasindicatedinFigure 3.DMSOserv esas
the negative control. A proapoptotic sensing ﬂuorescent dye
wasadded1hourposttreatment.Twophenomenaarereadily
observable. The focal points of ﬂuorescence indicate cells
undergoing apoptosis which increase at higher phorbol ester
concentrations. As shown in Figure 3, the normally adherent
293 cells detach from the plastic dish and become rounded,
while Jurkat T-cell aggregates in suspension disperse and
regress from a rounded morphology. While the eﬀects of
PKC modulating agents on cells have been well studied,
the consequences of PKC modulation on tissues and organ
systems have not. Our recent observations on modulating
PKC activity in zebraﬁsh indicate that the concentrations




























































Figure 4: Comparative chemical structures of PKC-modulating agents.
transcription, do not induce developmental or lethal eﬀects
in zebraﬁsh embryos or early-term larvae [56].
The overwhelming concern with regard to the admin-
istration of certain phorbol esters is tumor promotion [57,
58]. Cellular transformation is a notorious property of
PMA which occurs through the sustained action of PKC α
[58]. Importantly, PMA-related phorbols antagonize PMA-
mediatedtumorpromotionofPMA[59]whileDAGlactones
appear less likely to mediate cellular transformation as a
consequenceoftheirlowaﬃnityforPKCαand preferentially
targeting PKC θ [21, 60].
The toxicity proﬁle of PMA, alternatively referred to
as 12-O-tetradecanoylphorbol-13-acetate (TPA), has been
clinically evaluated. Low doses administered to patients
resulted in transient fever and mild dyspnea [61]. No renal
or hepatic complications were noted although one patient
suﬀered a grand mal seizure upon receiving a platelet
transfusion after PMA administration. Collectively, the overt
clinical side eﬀects of phorbol ester or macrolide lactone
administration to patients include respiratory distress syn-
drome, hypotension, and other toxicities due to the release
of proinﬂammatory cytokines via nonspeciﬁc cellular acti-





It has been observed that structural variants among the
phorbol ester family of agents diﬀer in their potency to
upregulate latent viral expression which likely relate to
diﬀerential PKC isoform aﬃnities for eﬀector targets [20,
40, 59]. In vitro concentrations of phorbol esters, required
for the upregulation of latent virus in patient primary cells,
a r ei nt h er a n g eo f0 . 1 μMt o1 0 μM as single treatment
agents [20, 45, 46]. The mechanistic basis for the diﬀerences
in eﬀective concentrations of agents relates to variations
in their chemical structure. As shown in Figure 4,b o t h
PMA and DPP have extended hydrophobic side groups
which are not present in the base structure of prostratin.6 Advances in Virology
These hydrophobic entities exposed outward from the
PKC/phorbol complex, likely associate with and retain the
complexes at the plasma membrane resulting in sustained
PKC action. Such sustained action can accentuate select
processesincludingtumorpromotionorapoptosiswhichare
not typical of prostratin treatment relative to PMA and DPP
at similar concentrations. On the basis of these observations,
it was proposed that the ancillary toxicities of PKC activators
could be minimized by altering select reactive groups to
present the most favorable clinical index.
Toward that goal, Hamer et al. synthesized and tested the
activityofseveralDAGanaloguesthatareagonistsofthePKC
pathway [60]. Among those assessed, LMC03 and LMC07
were less potent than other phorbols at upregulating the
proinﬂammatory cytokine, TNF-α. These compounds also
had decreased ability to downregulate cell surface expression
of CD4 and CXCR4 in A3.01 cells.
More recently, M´ arquez et al. demonstrated that phor-
bol-13-stearate eﬀectively activates latent HIV-1 expression
10-fold more potently than prostratin [40]. Like PMA and
prostratin, phorbol-13-stearate stimulates IKK-dependent
phosphorylation and degradation of IκB with subsequent
activation of NF-κB. Interestingly, phorbol-13-stearate treat-
ment results in the translocation of PKC isotypes α and δ
to diﬀerent cellular compartments than do prostratin and
PMA [40]. Clinical administration of these PKC-modulating
derivatives has not yet been reported.
8. Conclusion
The ongoing eﬀorts to formulate new lead compounds, to
upregulate latent HIV-1 through PKC modulation which
bear minimal clinical side eﬀects, appears to be a rational
approach toward the eradication of latent HIV reservoirs.
Diﬀerential PKC isoform targeting may be important since
those isotypes that modulate PKC downstream of PKC α,
exhibit fewer deleterious cellular and tissue side eﬀects. It is
unlikely that one singular therapeutic approach will achieve
complete reservoir ablation as multiple molecular mecha-
nisms can elicit or maintain HIV-1 latency [64]. The lessons
from HAART usage indicate that some form of combination
therapy with reservoir eradication agents, as well as multiple
dosing, could be of utility. Nonetheless, treatments, which
markedly accelerate the process of reservoir decay, should
be regarded as a signiﬁcant advancement toward the goal
of curing HIV-1 infection, as well as compelling, given the
considerable expense and notable side eﬀects associated with
the prolonged administration of HAART.
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